Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

Vivasure Medical, an Ireland-based developer of fully absorbable technology for percutaneous vessel closure, announced ...

A key highlight from NovoCure's earnings call was the announcement of European CE Mark approval for OptuneLua in the treatment of metastatic non-small cell lung cancer (NSCLC). The CE Mark allows ...

Roche has picked up a CE Mark approval in the EU for an artificial intelligence algorithm that can help doctors decide ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

today announced European CE mark approval of the PerQseal ® Elite vascular closure system, a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the ...

Vivasure Medical announced today that it received CE mark approval for its PerQseal Elite vascular closure system.

“Securing CE Mark approval for PerQseal Elite marks a ... We’re proud to bring this innovative technology to clinicians across Europe.” The PerQseal Elite vascular closure system is placed ...

today announced European CE mark approval of the PerQseal ® Elite vascular closure system, a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the ...